All lobbying filings

REGENERON PHARMACEUTICALS, INC

REGENERON PHARMACEUTICALS, INC filed a Q2 report for REGENERON PHARMACEUTICALS, INC on July 20, 2026.

Lobbying for REGENERON PHARMACEUTICALS, INC

All filings by REGENERON PHARMACEUTICALS, INC · Everything REGENERON PHARMACEUTICALS, INC has reported

Filing · LD-2 quarterly report Q2 report

Reporting period

2nd Quarter 2026

Apr 1 - June 30 · Posted Jul 20, 2026

Expenses

$630,000

What this organization spent lobbying with its own staff. Reported using the LDA's own definitions (method A): the three LDA methods count different costs, so an expenses figure is not comparable across filers that used different ones.

Client based in

New York

Official filing document

Government bodies contacted 2

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

Lobbying activity 5

Health Issues

Privacy legislation related to biopharmaceutical manufacturers; Food and Drug Administration issues related to biopharmaceutical manufacturers; National security issues related to biopharmaceutical manufacturers; Public-private contracts for innovation in the biopharmaceutical space.

Medicare/Medicaid

Medicare, Medicaid, and other drug pricing issues relating to biopharmaceutical manufacturers.

Intellectual property legislation related to biopharmaceutical manufacturers.

Trade (domestic/foreign)

Trade and tariff issues related to corporations.

Taxation/Internal Revenue Code

Tax and inflation issues related to corporations.

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.